Skip to content

D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia

D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00237809
Enrollment
104
Registered
2005-10-12
Start date
2002-09-30
Completion date
2012-09-30
Last updated
2017-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizoaffective Disorder, Schizophrenia

Brief summary

This study is based on the hypothesis that by increasing N-methyl-D-aspartic acid (NMDA) receptor function in the brain and thereby increasing the capacity of the brain to both form new connections and strengthen existing connections, schizophrenic patients may derive both greater and sustained benefit from cognitive retraining.

Detailed description

Patients with schizophrenia or schizoaffective disorder who are currently receiving antipsychotic medication will be randomly assigned in a double-blind manner to receive either D-serine (30 mg/kg) or placebo in addition to cognitive rehabilitation or a non-interactive placebo for 12 weeks.

Interventions

DRUGD-serine

D-serine (30 mg/kg)

BEHAVIORALCognitive Retraining (CRT)

Cognitive retraining therapy (CRT)

DRUGPlacebo

Placebo D-serine Drug

BEHAVIORALCognitive Retraining Placebo

Cognitive retraining therapy (CRT) control

Sponsors

National Alliance for Research on Schizophrenia and Depression
CollaboratorOTHER
Donaghue Medical Research Foundation
CollaboratorOTHER
Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of schizophrenia or schizoaffective disorder Exclusion * Pregnant or lactating

Design outcomes

Primary

MeasureTime frameDescription
Wisconsin Card Sorting Test (WCST)12 weeksThe WCST allows the clinician to speculate to the following frontal lobe functions: strategic planning, organized searching, utilizing environmental feedback to shift cognitive sets, directing behavior toward achieving a goal, and modulating impulsive responding. The test can be administered to those from 6.5 years to 89 years of age.The test takes approximately 12-20 minutes to carry out and generates a number of psychometric scores, including numbers, percentages, and percentiles of: categories achieved, trials, errors, and perseverative errors. Can be interpreted as: the greater the percentage, the greater the measured ability.
Hopkins Verbal Learning Test12 weeksThe Hopkins Verbal Learning Test is designed to assess verbal learning and memory (immediate recall, delayed recall, delayed recognition). The assessment takes approximately 5-10 minutes with a 25-minute delay to complete and 2 minutes to score. The greater the score, the greater the measured recall. The score ranges from 0 to 24.
Spatial Span- Total Score12 weeksThe Spatial Span subtest of the Wechsler Memory Scale can be used as an indicator of working memory and visuospatial processing. An increase in severity of impairment results in a decrease in Spatial Span Total Score. The range is 1 to 28.
Positive and Negative Syndrome Scale (PANSS)12 weeksThe PANSS is a handscored instrument. It uses 25 PANSS items organized into five scales: Negative, Positive, Dysphoric Mood, Activation, and Autistic Preoccupation. The PANSS is based on findings that schizophrenia comprises at least two distinct syndromes. The positive syndrome consists of productive symptoms, while the negative syndrome consists of deficit features. This distinction is useful when developing treatment plans because you can focus on the type of symptoms the patient is experiencing. It is also useful when studying the effects of medication (e.g., in clinical drug trials) because it allows you to determine which type of symptoms are being affected. PANSS Total score minimum = 30, maximum = 210. The greater the score, the greater the symptoms.

Secondary

MeasureTime frameDescription
Simpson-Angus Neurological Rating Scale12 weeksSimpson-Angus Scale (SAS) is a 10-item rating scale that has been used widely for assessment in both clinical practice and research settings. Items are rated for severity on a 0-4 scale, with definitions given for each anchor point. The highest possible score is 40.
UCSD Performance-Based Skills Assessment (UPSA)12 weeksThe UCSD Performance-Based Skills Assessment (UPSA) is a role-play test designed to evaluate a person's functional capacity in two selected areas of basic living skills. These areas include Finance and Communication. Subjects being tested utilize props to demonstrate how they perform everyday activities and are assessed on their actual performance. The higher the score, the better the performance of an individual. The scores range from 0 to 100.
Heinrichs-Carpenter Quality of Life Scale12 weeksThe Heinrichs-Carpenter Quality of Life Scale is a testing device. It has a range of possible scores, 0-126 used to evaluate social functioning & behavior in patients with schizophrenia-lower scores represent poorer mental health.

Countries

United States

Participant flow

Recruitment details

Subjects were enrolled between 2003 and 2008, with enrollment of subjects in India starting later (2005) and ending in 2008.

Pre-assignment details

132 subjects were screened for eligibility. After screening, eligible subjects were randomized to receive: D-serine+CRT, placebo D-serine+CRT, D-serine + control CRT, or placebo D-serine + control CRT. Randomization was stratified by screening performance IQ. Separate randomization schedules (block size= 4) were generated within IQ stratum.

Participants by arm

ArmCount
D-serine/Control
D-serine/control D-serine : D-serine (30 mg/kg)
27
Placebo/Cog Rehab
Placebo/cog rehab Cognitive retraining : Cog rehab
27
D-serine/Cog Rehab
D-serine/cog rehab D-serine : D-serine (30 mg/kg)
24
Placebo/Control
Placebo/control Cognitive retraining : Cog rehab
26
Total104

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003
Overall StudyLost to Follow-up111099

Baseline characteristics

CharacteristicD-serine/ControlPlacebo/Cog RehabD-serine/Cog RehabPlacebo/ControlTotal
Age, Continuous35.7500 years
STANDARD_DEVIATION 8.01889
34.4762 years
STANDARD_DEVIATION 8.76139
36.3158 years
STANDARD_DEVIATION 9.16547
34.4545 years
STANDARD_DEVIATION 9.3642
35.21 years
STANDARD_DEVIATION 8.72
Sex: Female, Male
Female
9 Participants5 Participants5 Participants7 Participants26 Participants
Sex: Female, Male
Male
18 Participants22 Participants19 Participants19 Participants78 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —— / —
other
Total, other adverse events
14 / 2714 / 2712 / 2418 / 26
serious
Total, serious adverse events
0 / 270 / 270 / 240 / 26

Outcome results

Primary

Hopkins Verbal Learning Test

The Hopkins Verbal Learning Test is designed to assess verbal learning and memory (immediate recall, delayed recall, delayed recognition). The assessment takes approximately 5-10 minutes with a 25-minute delay to complete and 2 minutes to score. The greater the score, the greater the measured recall. The score ranges from 0 to 24.

Time frame: 12 weeks

ArmMeasureValue (MEAN)Dispersion
D-serine/ControlHopkins Verbal Learning Test20.74 units on a scaleStandard Deviation 5.25
Placebo/Cog RehabHopkins Verbal Learning Test19.80 units on a scaleStandard Deviation 5.94
D-serine/Cog RehabHopkins Verbal Learning Test20.42 units on a scaleStandard Deviation 7.51
Placebo/ControlHopkins Verbal Learning Test21.45 units on a scaleStandard Deviation 5.85
Primary

Positive and Negative Syndrome Scale (PANSS)

The PANSS is a handscored instrument. It uses 25 PANSS items organized into five scales: Negative, Positive, Dysphoric Mood, Activation, and Autistic Preoccupation. The PANSS is based on findings that schizophrenia comprises at least two distinct syndromes. The positive syndrome consists of productive symptoms, while the negative syndrome consists of deficit features. This distinction is useful when developing treatment plans because you can focus on the type of symptoms the patient is experiencing. It is also useful when studying the effects of medication (e.g., in clinical drug trials) because it allows you to determine which type of symptoms are being affected. PANSS Total score minimum = 30, maximum = 210. The greater the score, the greater the symptoms.

Time frame: 12 weeks

ArmMeasureValue (MEAN)Dispersion
D-serine/ControlPositive and Negative Syndrome Scale (PANSS)53.30 units on a scaleStandard Deviation 13.58
Placebo/Cog RehabPositive and Negative Syndrome Scale (PANSS)52.01 units on a scaleStandard Deviation 13.34
D-serine/Cog RehabPositive and Negative Syndrome Scale (PANSS)53.79 units on a scaleStandard Deviation 12.76
Placebo/ControlPositive and Negative Syndrome Scale (PANSS)53.96 units on a scaleStandard Deviation 12.43
Primary

Spatial Span- Total Score

The Spatial Span subtest of the Wechsler Memory Scale can be used as an indicator of working memory and visuospatial processing. An increase in severity of impairment results in a decrease in Spatial Span Total Score. The range is 1 to 28.

Time frame: 12 weeks

ArmMeasureValue (MEAN)Dispersion
D-serine/ControlSpatial Span- Total Score13.59 units on a scaleStandard Deviation 4.18
Placebo/Cog RehabSpatial Span- Total Score13.88 units on a scaleStandard Deviation 4.2
D-serine/Cog RehabSpatial Span- Total Score13.21 units on a scaleStandard Deviation 3.23
Placebo/ControlSpatial Span- Total Score13.58 units on a scaleStandard Deviation 4.07
Primary

Wisconsin Card Sorting Test (WCST)

The WCST allows the clinician to speculate to the following frontal lobe functions: strategic planning, organized searching, utilizing environmental feedback to shift cognitive sets, directing behavior toward achieving a goal, and modulating impulsive responding. The test can be administered to those from 6.5 years to 89 years of age.The test takes approximately 12-20 minutes to carry out and generates a number of psychometric scores, including numbers, percentages, and percentiles of: categories achieved, trials, errors, and perseverative errors. Can be interpreted as: the greater the percentage, the greater the measured ability.

Time frame: 12 weeks

ArmMeasureValue (MEAN)Dispersion
D-serine/ControlWisconsin Card Sorting Test (WCST)38.43 percentage of correct responsesStandard Deviation 24.07
Placebo/Cog RehabWisconsin Card Sorting Test (WCST)35.79 percentage of correct responsesStandard Deviation 21.57
D-serine/Cog RehabWisconsin Card Sorting Test (WCST)43.14 percentage of correct responsesStandard Deviation 27.06
Placebo/ControlWisconsin Card Sorting Test (WCST)39.57 percentage of correct responsesStandard Deviation 22.31
Secondary

Heinrichs-Carpenter Quality of Life Scale

The Heinrichs-Carpenter Quality of Life Scale is a testing device. It has a range of possible scores, 0-126 used to evaluate social functioning & behavior in patients with schizophrenia-lower scores represent poorer mental health.

Time frame: 12 weeks

ArmMeasureValue (MEAN)Dispersion
D-serine/ControlHeinrichs-Carpenter Quality of Life Scale67.26 units on a scaleStandard Deviation 20.04
Placebo/Cog RehabHeinrichs-Carpenter Quality of Life Scale68.30 units on a scaleStandard Deviation 25.59
D-serine/Cog RehabHeinrichs-Carpenter Quality of Life Scale63.25 units on a scaleStandard Deviation 24.15
Placebo/ControlHeinrichs-Carpenter Quality of Life Scale63.92 units on a scaleStandard Deviation 19.53
Secondary

Simpson-Angus Neurological Rating Scale

Simpson-Angus Scale (SAS) is a 10-item rating scale that has been used widely for assessment in both clinical practice and research settings. Items are rated for severity on a 0-4 scale, with definitions given for each anchor point. The highest possible score is 40.

Time frame: 12 weeks

ArmMeasureValue (MEAN)Dispersion
D-serine/ControlSimpson-Angus Neurological Rating Scale1.41 units on a scaleStandard Deviation 2.53
Placebo/Cog RehabSimpson-Angus Neurological Rating Scale0.72 units on a scaleStandard Deviation 1.73
D-serine/Cog RehabSimpson-Angus Neurological Rating Scale1.04 units on a scaleStandard Deviation 1.27
Placebo/ControlSimpson-Angus Neurological Rating Scale1.81 units on a scaleStandard Deviation 2.25
Secondary

UCSD Performance-Based Skills Assessment (UPSA)

The UCSD Performance-Based Skills Assessment (UPSA) is a role-play test designed to evaluate a person's functional capacity in two selected areas of basic living skills. These areas include Finance and Communication. Subjects being tested utilize props to demonstrate how they perform everyday activities and are assessed on their actual performance. The higher the score, the better the performance of an individual. The scores range from 0 to 100.

Time frame: 12 weeks

ArmMeasureValue (MEAN)Dispersion
D-serine/ControlUCSD Performance-Based Skills Assessment (UPSA)34.19 units on a scaleStandard Deviation 9.41
Placebo/Cog RehabUCSD Performance-Based Skills Assessment (UPSA)32.80 units on a scaleStandard Deviation 10.98
D-serine/Cog RehabUCSD Performance-Based Skills Assessment (UPSA)32.60 units on a scaleStandard Deviation 13.82
Placebo/ControlUCSD Performance-Based Skills Assessment (UPSA)31.39 units on a scaleStandard Deviation 10.01

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026